Ophthotech Corp. has initiated the first of several planned expansion trials, in addition to the ongoing E10030 (Fovista) combination therapy phase III clinical program.
New York-Ophthotech Corp. has initiated the first of several planned expansion trials, in addition to the ongoing E10030 (Fovista) combination therapy phase III clinical program.
The expansion trials will investigate the potential role of the anti-platelet derived growth factor (anti-PDGF) combination therapy in reducing sub-retinal fibrosis, addressing sub-optimal treatment response, and reducing treatment burden in patients with wet age-related macular degeneration (AMD) receiving anti-vascular endothelial growth factor (anti-VEGF) monotherapy.
The first expansion trial is a phase IIa open-label study investigating the potential role of anti-PDGF therapy in combination with anti-VEGF therapy in reducing sub-retinal fibrosis in patients with wet AMD.
“The initiation of the . . . expansion studies continues our commitment to advance scientifically driven therapeutic options to address an unmet medical need in AMD,” said David R. Guyer, MD, chief executive officer and board chairman of Ophthotech. “Sub-retinal fibrosis is associated with poor visual outcome in patients receiving anti-VEGF monotherapy for wet AMD.
NEXT: Page 2
“The inhibition of fibrosis is an urgent and unmet medical need in wet AMD,” he continued.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.